In this article: research news about prednisone in Duchenne MD; tests for Duchenne and Becker MDs; and the latest progress in research for spinal muscular atrophy
On Jan. 10, the American Academy of Neurology (AAN) released its long-awaited report on the use of corticosteroids (prednisone or deflazacort) in Duchenne muscular dystrophy (DMD). The report is also published in the Jan. 11 issue of Neurology.
It finds that corticosteroids are beneficial in DMD, but that some drawbacks to their use must be considered. To see the report for physicians and a version for families, visit “Practice Guidelines” on the AAN Web site.
Known as a practice parameter, the report results from a review of relevant articles published from 1966 to 2004, of which 25 were chosen for detailed analysis. The AAN subcommittee preparing the report was composed mostly of MDA clinic directors and research grantees. Several of the 25 selected studies received MDA funding.
The report concluded that:
The subcommittee’s recommendations included:
Valerie Cwik, MDA’s medical director, said that while the guidelines are useful, they also identify many questions about corticosteroid therapy and DMD that remain unanswered.
MDA grantee Basil Petrof at the Meakins-Christie Laboratories and the Respiratory Division of McGill University in Montreal will continue to improve the efficiency of delivering “naked” (without viruses) DNA through the bloodstream to muscle cells, using funding from MDA that runs through 2007.
A group headed by Petrof that included MDA grantee George Karpati at McGill’s Montreal Neurological Institute recently found that reducing pressure from fluid buildup inside muscles may make delivery of naked DNA to muscles via arteries more effective.
The team, which published its findings online in Molecular Therapy on Oct. 28, found that by reducing the fluid pressure inside the leg muscles during the injection procedure, they could significantly increase the amount of DNA delivered to the muscles and minimize damage to muscle cells.
In experiments in pigs, the scientists reached some 60 percent of fibers in a muscle at the back of the leg after injecting DNA into a major artery in the thigh. Tests also indicated that lowering intramuscular fluid pressure buildup may have reduced damage to muscle fibers caused by such injections.
“Several groups are attempting to improve methods for delivering genes to muscle by injection into the bloodstream,” Petrof said. “We believe that intramuscular pressure monitoring is a simple and valuable tool for optimizing these efforts.”
Karpati added, “This method could be used for optimization of dystrophin gene delivery in appropriate clinical trials in Duchenne dystrophy patients.”
The Medical Genetics Laboratories at Baylor College of Medicine in Houston are now offering full screening for mutations (flaws) in the dystrophin gene, which underlie Duchenne muscular dystrophy (DMD) and Becker MD (BMD).
Standard tests only detect about 60 percent of DMD-causing mutations in the dystrophin gene and an uncertain percentage of BMD-causing mutations. However, it’s important for families to know exactly what mutation an affected member has, because such results may determine eligibility for a clinical trial, and may allow definitive prenatal and carrier testing.
The Baylor test, which was developed with MDA support of Madhuri Hegde in the Department of Molecular and Human Genetics, scans the dystrophin gene using denaturing high-pressure liquid chromatography (DHPLC), a process designed to detect almost all dystrophin mutations.
For more information, visit the Medical Genetics Laboratories' Web site, or call (800) 411-GENE (4363).
Tests that examine the entire dystrophin gene are also offered at the Utah Genome Depot in Salt Lake City (801-581-6956); and City of Hope National Medical Center’s Clinical Molecular Diagnostic Laboratory in Duarte, Calif. (888-826-4362).
Spinal muscular atrophy (SMA) is caused by a deficiency of the survival of motor neuron (SMN) protein, which is made by the SMN1 gene and to a far lesser extent by the SMN2 gene. Research is focused on improving SMN protein levels through insertion of SMN genes or increasing production from SMN2 genes.
Researchers at Ohio State University in Columbus and Oxford (England) BioMedica have developed a way of delivering therapeutic genes to mice with a disease resembling human SMA.
Mice that received SMN genes developed SMA symptoms later and lived a few days longer than did mice that received injections with no genes or no treatment at all.
The investigators first inserted the genes into transport vehicles (vectors) made from an altered version of the equine infectious anemia virus (EIAV), a member of the lentivirus family. They then injected the virus-coated genes into the muscles of the back legs, diaphragms, rib areas, faces and tongues of the SMN-deficient mice. They say the genes moved from muscle fibers up nerve fibers.
The authors, who published their results in the December issue of the Journal of Clinical Investigation, write that the findings “are indicative that gene transfer using lentivector expressing SMN at onset of disease induces not only an extension in life span, but also results in a delay in the motor phenotype [movement functions] in a severe model of SMA.”
They also note, however, that the effects on the mouse disease were surprisingly minimal, given that SMN was found in a large percentage of examined nerve cells.
The study authors included Arthur Burghes, a molecular biologist at Ohio State who, with MDA funding, contributed significantly to the understanding of SMA genetics in the late 1990s.
A project funded by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health is searching for chemical compounds that can be developed into medications to treat SMA.
Known as the SMA Project, the drug screen is aimed at finding substances that increase SMN2’s output of the SMN protein.
“We have good candidate drugs from studies in other systems,” grantee Michael Terns, associate professor of biochemistry and molecular biology at the University of Georgia in Athens, said. “In addition, there are libraries of compounds available for testing to see if protein concentrations go up without having to know the mechanism behind it.”
The Georgia researchers will use NIH-approved human embryonic stem cells to test the ability of compounds to increase SMN production. Additional grants were given to Johns Hopkins University in Baltimore and Ohio State University in Columbus.
A team of investigators has found that indoprofen, a nonsteroidal anti-inflammatory agent, slightly increases production of the needed SMN protein in cells taken from people with severe SMA.
Drug responses from cells in a lab dish don’t always match responses in animals or people, but cell-based screens are often a first step toward drug discovery
The researchers, in the November issue of Chemistry & Biology, say the drug also led to more gems, structures that are reduced in SMA-affected cells. And SMA-affected developing embryos showed a trend toward greater survival when their mothers were given indoprofen.
Among the study team members were Glenn Morris of the Robert Jones and Agnes Hunt Orthopaedic Hospital in Oswestry, United Kingdom; Arthur Burghes of Ohio State University in Columbus; and Elliot Androphy of the University of Massachusetts in Worcester, all of whom have received MDA funding to study SMN.
The authors note that no other tested compounds from this class of anti-inflammatory medications increased SMN production.
The indoprofen finding wasn’t a result of the NINDS SMA Project.